Fresenius Kabi has launched a new generic version of Cetrorelix Acetate for Injection, a medication used in reproductive health treatments, expanding its portfolio of women’s health products. The new option, which is available immediately, offers a cost-effective alternative for women undergoing fertility treatments. The injection kit includes one single-dose vial (0.25 mg cetrorelix), a pre-filled syringe with sterile water for injection, and two needles (20-gauge and 27-gauge), providing a comprehensive solution for healthcare providers and patients.
“Our newest launch of Cetrorelix Acetate for Injection further demonstrates Fresenius Kabi’s strength in broadening access to cost-effective injectable medicines and our commitment to women’s health,” said Arun Verma, president of Fresenius Kabi USA.
Cetrorelix Acetate for Injection is a therapeutic equivalent to EMD Serono’s Cetrotide (0.25 mg) and is used to prevent premature ovulation in women undergoing hormone treatment for ovarian stimulation. By blocking the effects of gonadotropin-releasing hormone (GnRH), it helps ensure that eggs remain suitable for fertilization during the assisted reproductive technology (ART) process.
With the demand for fertility services on the rise, cost-effective options like this new generic are increasingly vital. According to the American Society for Reproductive Medicine, the number of babies born through in vitro fertilization (IVF) in the U.S. increased from 89,208 in 2021 to 91,771 in 2022. This growth reflects the continued demand for fertility treatments, with 2.5% of all births in the U.S. now resulting from successful ART cyclesrengthening Commitment to Women’s Health
The introduction of Cetrorelix Acetate for Injection marks the fourth addition to Fresenius Kabi’s expanding portfolio of women’s health products, which also includes Chorionic Gonadotropin for Injection, USP (hCG); Progesterone Injection, USP; and Ganirelix Acetate Injection. Fresenius Kabi plans to continue expanding its women’s health offerings to meet the growing demand for reproductive health options.
